The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1486
January 18, 2016
View Complete Issue         Table of Contents 2019 
Elvitegravir (Vitekta) for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Elvitegravir (Vitekta) for HIV
January 18, 2016 (Issue: 1486)
The FDA has approved elvitegravir (Vitekta – Gilead), an integrase strand transfer inhibitor (INSTI), for use with a protease inhibitor (PI) plus ritonavir and other antiretroviral drugs for treatment of HIV-1 infection in treatment-experienced...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Elvitegravir (Vitekta) for HIV
Article code: 1486d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.